Total Payments
$6,390
2024 Payments
$2,023
Companies
21
Transactions
93
Medicare Patients
8,983
Medicare Billing
$961,544
Payment Breakdown by Category
Food & Beverage$6,098 (95.4%)
Education$291.46 (4.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,098 | 89 | 95.4% |
| Education | $291.46 | 4 | 4.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,042 | 25 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,171 | 22 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $758.89 | 14 | $0 (2024) |
| GENZYME CORPORATION | $476.43 | 4 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $366.87 | 4 | $0 (2024) |
| Novo Nordisk Inc | $228.30 | 2 | $0 (2024) |
| ABBVIE INC. | $195.94 | 2 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $149.98 | 1 | $0 (2024) |
| Mylan Specialty L.P. | $136.03 | 2 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $124.80 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,023 | 22 | AstraZeneca Pharmaceuticals LP ($830.72) |
| 2023 | $1,986 | 24 | AstraZeneca Pharmaceuticals LP ($584.74) |
| 2022 | $1,387 | 15 | AstraZeneca Pharmaceuticals LP ($425.94) |
| 2021 | $130.05 | 2 | Acerta Pharma LLC ($77.52) |
| 2020 | $41.49 | 1 | AstraZeneca Pharmaceuticals LP ($41.49) |
| 2019 | $100.19 | 3 | Allergan Inc. ($62.19) |
| 2018 | $38.70 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($38.70) |
| 2017 | $682.98 | 25 | Boehringer Ingelheim Pharmaceuticals, Inc. ($166.50) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $3.97 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $111.76 | General |
| Category: Respiratory | ||||||
| 10/24/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Education | In-kind items and services | $99.26 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/23/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $123.33 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $3.04 | General |
| Category: Respiratory | ||||||
| 10/09/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $3.44 | General |
| Category: RESPIRATORY | ||||||
| 09/11/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $109.89 | General |
| Category: Respiratory | ||||||
| 09/10/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $126.08 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/13/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $121.88 | General |
| Category: IMMUNOLOGY | ||||||
| 08/01/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $113.04 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $122.45 | General |
| Category: Obesity | ||||||
| 06/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $149.98 | General |
| Category: Cardio-renal | ||||||
| 06/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $99.70 | General |
| 05/23/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $133.35 | General |
| Category: Respiratory | ||||||
| 05/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $114.73 | General |
| Category: Immunology | ||||||
| 05/02/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $119.88 | General |
| Category: RESPIRATORY | ||||||
| 04/08/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $4.21 | General |
| Category: RESPIRATORY | ||||||
| 03/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $111.22 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $123.32 | General |
| Category: Respiratory | ||||||
| 03/08/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $3.26 | General |
| Category: RESPIRATORY | ||||||
| 03/06/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $112.06 | General |
| Category: Respiratory | ||||||
| 02/01/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $113.41 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $72.76 | General |
| Category: Respiratory | ||||||
| 12/06/2023 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $117.73 | General |
| Category: Oncology | ||||||
| 11/29/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SPIRIVA RESPIMAT | Food and Beverage | In-kind items and services | $122.00 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,117 | 3,755 | $754,790 | $222,029 |
| 2022 | 28 | 2,276 | 5,111 | $908,876 | $253,578 |
| 2021 | 19 | 2,201 | 3,627 | $785,391 | $230,279 |
| 2020 | 21 | 2,389 | 4,049 | $875,958 | $255,658 |
Total Patients
8,983
Total Services
16,542
Medicare Billing
$961,544
Procedure Codes
95
All Medicare Procedures & Services
95 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 667 | 1,795 | $506,190 | $159,550 | 31.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 73 | 203 | $39,991 | $12,503 | 31.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 89 | 89 | $36,490 | $10,624 | 29.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 63 | 67 | $25,058 | $6,770 | 27.0% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 23 | 23 | $10,350 | $6,487 | 62.7% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 75 | 75 | $5,625 | $5,513 | 98.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 47 | 103 | $11,021 | $4,012 | 36.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 80 | 80 | $2,640 | $2,373 | 89.9% |
| 31628 | Biopsy of lobe of lung using an endoscope, 1 lobe | Facility | 2023 | 18 | 18 | $36,216 | $2,030 | 5.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 245 | 255 | $14,790 | $1,936 | 13.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 95 | 102 | $13,409 | $1,722 | 12.8% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 247 | 254 | $12,700 | $1,678 | 13.2% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 157 | 157 | $10,519 | $1,440 | 13.7% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 13 | 26 | $4,888 | $1,261 | 25.8% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 11 | 139 | $8,618 | $1,156 | 13.4% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 95 | 96 | $6,432 | $814.44 | 12.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 21 | 23 | $4,600 | $793.34 | 17.2% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 24 | 24 | $768.00 | $711.84 | 92.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 45 | 51 | $1,479 | $428.40 | 29.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 23 | $1,334 | $213.40 | 16.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 18 | 152 | $1,672 | $14.43 | 0.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 629 | 1,832 | $494,608 | $159,218 | 32.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 123 | 363 | $69,239 | $20,158 | 29.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 82 | 83 | $44,204 | $12,492 | 28.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 45 | 113 | $30,989 | $9,036 | 29.2% |
About Dr. Usman Cheema, MD
Dr. Usman Cheema, MD is a Pulmonary Disease healthcare provider based in Galesburg, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518071760.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Usman Cheema, MD has received a total of $6,390 in payments from pharmaceutical and medical device companies, with $2,023 received in 2024. These payments were reported across 93 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($6,098).
As a Medicare-enrolled provider, Cheema has provided services to 8,983 Medicare beneficiaries, totaling 16,542 services with total Medicare billing of $961,544. Data is available for 4 years (2020–2023), covering 95 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Galesburg, IL
- Active Since 08/17/2006
- Last Updated 05/19/2015
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1518071760
Products in Payments
- DUPIXENT (Biological) $843.30
- FASENRA (Biological) $750.43
- TEZSPIRE (Biological) $632.92
- AREXVY (Drug) $352.60
- JARDIANCE (Drug) $352.29
- NUCALA (Biological) $335.35
- FARXIGA (Drug) $260.65
- OFEV (Drug) $238.86
- BREZTRI (Drug) $186.21
- TRELEGY ELLIPTA (Drug) $152.63
- Kerendia (Drug) $149.98
- BEVESPI AEROSPHERE (Drug) $136.20
- SOLIQUA 100/33 (Biological) $124.80
- YUPELRI (Drug) $123.33
- Wegovy (Drug) $122.45
- Cologuard Collection Kit (Device) $117.73
- ACTHAR (Biological) $113.92
- AIRSUPRA (Drug) $112.06
- CAMZYOS (Drug) $111.27
- Ozempic (Drug) $105.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.